Advertisement
U.S. markets open in 1 hour 57 minutes
S&P Futures
4,581.75 +6.75 (+0.15%) Dow Futures
36,223.00 +34.00 (+0.09%) Nasdaq Futures
15,929.75 +21.00 (+0.13%) Russell 2000 Futures
1,865.80 +6.00 (+0.32%) Crude Oil
71.64 -0.68 (-0.94%) Gold
2,039.80 +3.50 (+0.17%)
Puma Biotechnology, Inc. (PBYI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 3.8000 |
| Open | 3.8700 |
| Bid | 2.0000 x 800 |
| Ask | 4.3300 x 1000 |
| Day's Range | 3.7100 - 3.9800 |
| 52 Week Range | 2.1300 - 5.1600 |
| Volume | |
| Avg. Volume | 193,996 |
| Market Cap | 177.441M |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | 53.29 |
| EPS (TTM) | 0.0700 |
| Earnings Date | Feb 29, 2024 - Mar 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.67 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
52% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for PBYI
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Puma Biotechnology IncAnalyst Report: Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.RatingFair ValueEconomic Moat27 days agoMorningstar
ZacksAlterity (ATHE) Up on Preclinical Parkinson's Treatment Data
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
ZacksAstraZeneca (AZN) to Discontinue Two Studies on Lokelma
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
ZacksAbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study
Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.